Kao Corporation
1-14-10 Nihonbashi Kayabacho 1-chome, Tokyo, Chuo-ku, 103-8210, Japan
Overview
Kao Corporation is a chemical and cosmetics company, developing consumer product business that targets general consumers. Business segments that the company caters to the consumers include the beauty care business in which it offers prestige cosmetics, and premium skin care and hair care products; the human health care business with products that include functional health beverages and feminine and baby care products; and the fabric and home care business, which includes laundry detergents and household cleaners. Kao Corporation also develops chemical products that meet the various needs of industry. Founded in 1887, the company is headquartered in Tokyo, Japan.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Beauty
- Chemical
- Consumer Goods
- Health Care
- Manufacturing
- Retail
Investment portfolio
- Epsilon Molecular Engineering
Participated · Series A · Dec 2020
Epsilon Molecular Engineering (EME) creates proprietary cDNA display libraries for VHH and cyclic peptides using evolutionary molecular engineering and a high-throughput system that leverages next-generation sequencing, fluorescence-activated cell sorting, and AI. The company focuses on drug discovery in the medical field, developing biological and medium-sized molecular drug candidates and exploring VHH applications in cell and gene therapy. EME conducts collaborative R&D with pharmaceutical manufacturers and research institutions while also advancing an internal pipeline and early-stage development partnerships. The firm recently announced a VHH that can inhibit COVID-19 infection through collaborative research with Kitasato University and Kao Corporation. EME plans to accelerate collaborative research with pharmaceutical manufacturers and internal research using its pipeline to advance next-generation biotechnology-based drug discovery. Founded in 2016, the company aims to translate its screening and design technologies into therapeutic pharmaceuticals.
Team
Yoshihiro Hasebe
President and CEO
Tomiro Nagase
Founder